MedTrace Logo

Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease

NCT01438021 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-11-09

No results posted yet for this study

Summary

This pilot clinical trial studies continuous intraventricular methotrexate in treating patients with leptomeningeal disease. Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs directly into the ventricles may be an effective treatment for patients with leptomeningeal disease

Conditions

  • Leptomeningeal Metastases

Interventions

OTHER

pharmacological study

Correlative studies

DRUG

methotrexate

Given intraventricularly

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Mike Chen, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438021 on ClinicalTrials.gov